(4S,4aS,5aR,12aS)-9-(5-azaspiro[2.4]heptan-5-ylmethyl)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide | 1420294-54-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 英文名称: (4S,4aS,5aR,12aS)-9-(5-azaspiro[2.4]heptan-5-ylmethyl)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
• CAS: 1420294-54-7
• 化学式: C₃₀H₃₈N₄O₇
• 分子量: 566.654
• InChiKey: ZGKRENQCKZXYKL-YJUULGSPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.17
• 重原子数：
  41.0
• 可旋转键数：
  5.0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  167.87
• 氢给体数：
  5.0
• 氢受体数：
  10.0

文献信息

• 9-AMINOMETHYL SUBSTITUTED TETRACYCLINE COMPOUNDS
  申请人：Zhang Hui

  公开号：US20140179638A1

  公开（公告）日：2014-06-26

  The present invention relates to 9-aminomethyl substituted tetracycline compounds represented by formula (I), or pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, as well as a method for preparing these compounds and a pharmaceutical composition comprising the same. The present invention relates also to a use of these compounds in the preparation of a medicament for the treatment and/or prophylaxis of tetracycline drug-sensitive disease. wherein, R 2a , R 2b , R 3 , R 4a , R 4b , R 5 , R 6a , R 6b , R 7 , R 8 , R 9a , R 9b , R 10 , R 11 , R 12 , R 13a and R 13b are each independently as defined in the description.

  本发明涉及由式(I)表示的9-氨甲基取代四环素化合物，或其药学上可接受的盐、前药、溶剂化合物或异构体，以及制备这些化合物的方法和包含其的药物组合物。本发明还涉及这些化合物在制备用于治疗和/或预防四环素药物敏感疾病的药物中的用途。其中，R2a、R2b、R3、R4a、R4b、R5、R6a、R6b、R7、R8、R9a、R9b、R10、R11、R12、R13a和R13b各自独立地如描述中所定义。
• 9-AMINOMETHYL SUBSTITUTED TETRACYCLINE COMPOUND
  申请人：KBP Biosciences Co., Ltd.

  公开号：EP2738156A1

  公开（公告）日：2014-06-04

  The present invention relates to 9-aminomethyl substituted tetracycline compounds represented by formula (I), or pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, as well as a method for preparing these compounds and a pharmaceutical composition comprising the same. The present invention relates also to a use of these compounds in the preparation of a medicament for the treatment and/or prophylaxis of tetracycline drug-sensitive disease. wherein, R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R7, R8, R9a, R9b, R10, R11, R12, R13a and R13b are each independently as defined in the description.

  本发明涉及由式(I)代表的9-氨甲基取代的四环素化合物，或其药学上可接受的盐、原药、溶媒或异构体，以及制备这些化合物和包含这些化合物的药物组合物的方法。本发明还涉及这些化合物在制备治疗和/或预防四环素药物敏感性疾病的药物中的用途。 其中，R2a、R2b、R3、R4a、R4b、R5、R6a、R6b、R7、R8、R9a、R9b、R10、R11、R12、R13a 和 R13b 各自独立地如描述中所定义。
• METHODS OF TREATING MYCOBACTERIAL INFECTIONS USING TETRACYCLINE COMPOUNDS
  申请人：Paratek Pharmaceuticals, Inc.

  公开号：US20210346408A1

  公开（公告）日：2021-11-11

  The present invention provides methods of treating mycobacterial infections or mycobacterial diseases by administering a tetracycline compound, e.g., omadacycline, or a pharmaceutically acceptable salt thereof.
• US9365499B2
  申请人：——

  公开号：US9365499B2

  公开（公告）日：2016-06-14